A Phase Ib/IIa Open-Label, Escalating-Doses Study, of the Safety and Tolerability of Single Daily Doses of CEQ508, an RNAi-Based Therapy for Familial Adenomatous Polyposis

Trial Profile

A Phase Ib/IIa Open-Label, Escalating-Doses Study, of the Safety and Tolerability of Single Daily Doses of CEQ508, an RNAi-Based Therapy for Familial Adenomatous Polyposis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2017

At a glance

  • Drugs CEQ 508 (Primary)
  • Indications Colorectal cancer; Familial adenomatous polyposis
  • Focus Adverse reactions; Proof of concept
  • Acronyms START-FAP
  • Most Recent Events

    • 30 May 2017 Data from this trial will be presented at the 22nd Annual Meeting of the RNA Society 2017, as reported in a Marina Biotech media release.
    • 13 Mar 2017 Status changed from recruiting to completed, according to a Marina Biotech media release.
    • 13 Mar 2017 Safety and tolerability findings from this trial will be presented at the Society of Toxicology 56th Annual Meeting, according to a Marina Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top